Q3 results for Pfizer were solid, with adjusted earnings and revenue surpassing expectations. The current drop in share price seems excessive and may be driven by liquidity concerns rather than underlying performance issues. The significant decline in expected sales for COVID products is concerning, but overall, the fundamentals appear stable. This drop could present a buying opportunity if it’s mainly a liquidity grab
註釋
28.8 needs some type of confirmation, whether it's a retest or very strong orders. This level is crucial for assessing the market's next move註釋
Small entry now 28.250註釋
locked in 50% with a 1.3% gain x40 levrage. Holding rest BOS
免責聲明
這些資訊和出版物並不意味著也不構成TradingView提供或認可的金融、投資、交易或其他類型的意見或建議。請在使用條款閱讀更多資訊。